Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 72

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 72
---

30, 2024. The decrease in cash of $127,767 is primarily due to the cost of operations of $7,874,647, investment in equity securities of
$500,000 and repayments of finance agreement of $971,231, partially offset by funding totaling $9,354,003
related to private placements and proceeds from note payables during the period.

Equity 

On
April 8, 2025, the Company issued 15,000,000 shares of Common Stock valued at $6,058,500 pursuant to the Stock Purchase Agreement of Biosymetrics,
Inc. (see Note 10 to the Financial Statements).

On January 21, 2025, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer of Renovaro Cube valued at $177,500 (see
Note 10 to the Financial Statements).

On October 17, 2024, the Company
issued 160,000 shares of Common Stock for consulting services valued at $118,400 (see
Note 10 to the Financial Statements).

On October 14, 2024, the Company
issued 500,000 shares of Common Stock for consulting services valued at $275,000 (see
Note 10 to the Financial Statements).

On October 14, 2024, the Company
issued 250,000 shares of Common Stock to its Chief Executive Officer valued at $137,500 (see
Note 10 to the Financial Statements).

On August 1, 2024, the Company
issued 2,000,000 shares of Common Stock for consulting services valued at $1,400,000 (see
Note 10 to the Financial Statements).

Debt

Convertible Notes Payable —

The January 2024 Note —
On January 12, 2024, the Company entered into Subscription Agreements with an investor to issue a Convertible Promissory Note for an aggregate
principal amount of $125,000 (the “January 2024 Note”). The Company received a total of $125,000 in gross proceeds. The
January 2024 Note bears an interest rate of 12% per annum and matured on December 29, 2024. The Company is required to pay interest quarterly,
in arrears, in cash, on the first day of each quarter of each year following the issue date prior to the maturity of the January 2024
Note.